LifeSci Events’ Post

The covalency renaissance is heating up, as funding and collaboration fuel the development of chemoproteomic platforms and innovative modalities for hard-to-drug targets. December's 2nd Covalent Drug Discovery & Development Summit will reunite 100+ covalency specialists to deep dive into topics like: 🔹 Overcoming challenges in balancing reactivity and sensitivity with advanced screening cascades with Genentech, Scorpion Therapeutics, Amgen and Covant Therapeutics 🔹 Unlocking novel warheads for covalent screening of histidine, tyrosine and lysine residues to expand the druggable proteome with Hyku Biosciences, Bayer and Nexo Therapeutics 🔹 Exploring the advancing paradigm of covalent PROTACs and monovalents with the latest developments from Vividion Therapeutics, Inc., Baylor College of Medicine, Pfizer and Harvard University Download your copy of the program here: https://ter.li/76az03 #covalent #covalency #drugdiscovery #smallmolecule

Vancouver Biotech Inks Partnership with Novo Nordisk Worth Up to $800 Million NanoVation Therapeutics, a Vancouver company co-founded by biotech magnate Pieter Cullis, has struck a partnership with Danish pharmaceutical company Novo Nordisk that could be worth up to $800 million. The two companies will collaborate on the development of gene-editing therapies for certain rare genetic diseases. Under terms of the deal, Novo Nordisk will get an exclusive license to use NanoVation’s lipid nanoparticle technology for two lead programs, and NanoVation will receive up to $600 million in cash and milestone payments. NanoVation may also be eligible for tiered royalties on future product sales. NanoVation Therapeutics developed technology called long-circulating lipid nanoparticle (lcLNP) that overcomes certain barriers to nucleic acid delivery. https://lnkd.in/ghH4eJ35 #aspenalert #biotech #bioprocess

🚀 We’ll be at TIDES in Hamburg next week! Join us from November 11-14 as Luísa Aguiar presents her poster, "Greener Synthesis and Purification Solutions in the New Era of Peptide Therapeutics." 🌱 This is a fantastic opportunity to delve into sustainable advancements in peptide development and discuss the trends shaping the future of the field. Let’s connect at booth #316! Our experts, Cátia Teixeira and Luísa Aguiar, look forward to sharing how our PurePep solutions can take your peptide projects to the next level. 💡 The peptide therapeutics landscape is rapidly evolving, driven by two major trends: ⭐ Innovative Screening Platforms: Chemical and display screening platforms are becoming the new standard for target-based drug development, enriching the preclinical pipeline significantly. ⭐ GLP-1 Analogs Success: The breakthrough in GLP-1 analogs for weight loss and obesity is transforming pharmaceutical interest in peptides, leading to high demand and a capacity crunch in synthesis. We’re here to help you navigate these changes—see you in Hamburg! #purepep #forpeptidescientists #synthesis #purification

🔱 Lambda Biologics, which studies researchers, contemplates ways to conduct experiments more accurately and quickly. And we want researchers to enjoy convenient research lives with advanced services. Entrust your tests to our platform and use the MyLab service. Lambda Biologics, where researchers who study researchers gather, now offers online one-stop services for faster and more comfortable research. MyLab One-Stop Virtual Lab by Lambda Biologics #bio #biology #lambdabiologics #mylab #animalfreesolution #cro #preclinicalcro #biohealth #lab #organoid

Opening officially soon

Peptide Therapeutics: Is 2025 the Goldilocks Year? Join us for the Peptide Industry Leaders’ Panel Discussion, where top minds will explore game-changing breakthroughs, evolving challenges, and where the excitement is building in peptide-based therapeutics. Find out more: https://ter.li/03yjit Our Expert Panel: 💡 Cameron Pye, CEO, Unnatural Products 💡 Tomi Sawyer, Chief Drug Hunter & President, Maestro Therapeutics 💡 Pete Gough, CSO, Nimble Therapeutics 💡 Abbas Walji, Senior Director, Discovery Chemistry, Merck What to expect: 🔍 SWOT analysis of peptide-based therapeutics 🔍 Insights into overcoming scientific bottlenecks 🔍 Positioning peptides against market competitors Don’t miss your chance to gain insider perspectives—and if you register this week, you can save up to $900! https://ter.li/03yjit

Two must-attend sessions at the Oligonucleotide Therapeutics Xchange - Maryland 2024, 30 October, that you won't want to miss! Secure your free pass: https://lnkd.in/eWms8KbQ 🎯 Sponsor-led Roundtable Discussion: "Manufacturing n-of-1 Batches - Helping 1 Patient at a Time?" ⏰ 11:25 AM - 12:25 PM Join us for a sponsor-led roundtable discussion where we'll delve into the intricacies of manufacturing n-of-1 batches—a groundbreaking approach that could revolutionize personalized medicine, one patient at a time. This is a unique opportunity to engage with industry experts, exchange ideas, and explore innovative strategies in oligonucleotide manufacturing. 🎤 Poster Presentation: "Thiophosphoramidate Morpholino Oligonucleotides (TMOs): A Novel Class of PMOs Compatible With Conventional Automated Oligonucleotide Synthesis" ⏰ 3:15 PM - 3:45 PM Presented by Jeremy Little, Director of Custom Oligonucleotides at ChemGenes this session will showcase the latest advancements in TMOs—a novel class of PMOs that are set to enhance oligonucleotide synthesis. With over a decade of experience in nucleic acid drug discovery and oligonucleotide manufacturing, Jeremy brings unparalleled expertise to the table. Whether you're involved in biotech, pharma, or are just passionate about the future of oligonucleotide therapeutics, these sessions are invaluable. 💊Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. #LifeSciences #PrecisionMedicine #NucleicAcids #Pharmaceuticals #MedicalInnovation #Healthcare #Biotechnology #DrugDevelopment #MolecularBiology #ScientificResearch #GeneTherapy #OligonucleotideSynthesis #Biopharma #FutureOfMedicine #BiotechIndustry #InnovationInHealthcare #PharmaResearch #MedicinalChemistry #ClinicalResearch #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

Regenerative Medicine Market Size, Share & Trends Download PDF Brochure: https://lnkd.in/d6eZ9Wmv The global regenerative medicine market, valued at $16.0 billion in 2023, is projected to reach $49.0 billion by 2028, growing at a CAGR of 25.1%. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Novartis Biogen Gilead Sciences Sarepta Therapeutics Amgen Smith+Nephew Medipost JCR Pharmaceuticals TakedaPharmaceutical Nordics AB Corestem Inc Vericel® Corporation MiMedx Organogenesis Medtronic Bristol Myers Squibb Orthocell Ltd Mesoblast Limited BioRestorative Therapies, Inc. Anterogen bluebird bio Stempeutics Research Private Limited Aspect Biosystems #RegenerativeMedicine #StemCells #TissueEngineering #Biotechnology #HealthcareInnovation #MedicalResearch #CellTherapy #Regeneration

🌱💡 Empowering Cancer Treatment's Future: Tissue Dynamics and OrganoSpheres Revolutionize Health with Organoid Robotics and AI! #EmpoweringCancerTreatment #OrganoidRobotics #AIInnovation #HealthRevolution #TissueDynamics #OrganoSpheres #FutureOfHealthcare #CuttingEdgeTech

𝐍𝐞𝐞𝐝 𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬? 𝐖𝐞 𝐝𝐞𝐥𝐢𝐯𝐞𝐫! For over 30 years, Intavis Peptide Services has been a leading expert in the peptide industry. Renowned for producing 𝐡𝐢𝐠𝐡-𝐪𝐮𝐚𝐥𝐢𝐭𝐲 𝐜𝐮𝐬𝐭𝐨𝐦 𝐚𝐧𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐩𝐞𝐩𝐭𝐢𝐝𝐞𝐬, as well as pioneering 𝐩𝐞𝐩𝐭𝐢𝐝𝐞-𝐛𝐚𝐬𝐞𝐝 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬, we conduct all our production and services in our state-of-the-art facilities in Tübingen, Germany. In case you are planning in-vitro peptide research or a clinical trial on peptide therapeutics talk to our expert advisors now! Find the link in the comment. #ClinicalPeptides #PeptideProduction #Biotechnology #peptides